Rui Zhang
Rheumatology · Nashua, NHNPI 1588008452
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 61 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 15 manufacturers, the largest accounting for just 18.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $480 and has fallen 68.8% since, to $150 in 2025.
Across 61 payments — averaging $26.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$305
- Sanofi$220
- AstraZeneca$218
- Johnson & Johnson$211
- AbbVie$163
- UCB, Inc.$126
- plus $401 from 9 others
What the payments were for
- Food & beverage$1,644100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 12 | $305 |
| Sanofi | 11 | $220 |
| AstraZeneca | 4 | $218 |
| Johnson & Johnson | 8 | $211 |
| AbbVie | 4 | $163 |
| UCB, Inc. | 6 | $126 |
| Lilly USA, LLC | 6 | $113 |
| Relievant Medsystems, Inc. | 1 | $96 |
| GSK | 3 | $52 |
| Pacira Therapeutics, Inc. | 1 | $36 |
| Bristol Myers Squibb | 1 | $29 |
| Mallinckrodt Enterprises LLC | 1 | $28 |
| Pfizer | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Genentech USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SAPHNELO$102
How this compares
$1,644 in reported general payments places this provider in the 80th percentile of 48 rheumatology providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 54 | $404,699 |
| RinvoqUpadacitinib | 33 | $281,735 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 34 | $256,006 |
| SimponiGolimumab | 22 | $192,069 |
| EnbrelEtanercept | 18 | $156,484 |
| Enbrel SureclickEtanercept | 20 | $141,400 |
| Orencia ClickjectAbatacept | 23 | $128,740 |
| BenlystaBelimumab | 25 | $122,501 |
| OtezlaApremilast | 14 | $86,427 |
| Taltz AutoinjectorIxekizumab | 12 | $81,400 |
| OrenciaAbatacept | 14 | $77,529 |
| Actemra ActpenTocilizumab | 11 | $30,833 |
| SavellaMilnacipran Hcl | 24 | $21,868 |
| Hydroxychloroquine Sulfate | 206 | $7,568 |
| MethotrexateMethotrexate Sodium | 285 | $6,579 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Savella | $163 | $303,60357 claims |
| AmgenEnbrel, Otezla | $305 | $242,91132 claims |
| Johnson & JohnsonSimponi | $211 | $192,06922 claims |
| GSKBenlysta | $52 | $122,50125 claims |
| E.r. Squibb & Sons, L.L.C.Orencia | $16 | $77,52914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 48 rheumatology providers in New Hampshire.
Other rheumatology in Nashua
- John GormanNashua$2K
- Kalyani GovindarajuNashua$1K
- Lyudmila KirillovaNashua$1K
- Daniel TseytlinNashua$184
- Caryn LibbeyNashua$23
- May AldaabilNashua$0
- Angelica GonzalezNashua$0
- Jonathan KrantPeterborough$328K
- William RigbyLebanon$83K
- Naureen MirzaManchester$67K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.